Health TrialsbyHealthPanel

Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

2

Review clinical trials related to Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

This is a prospective, single-center, randomized, open-label, two-arm Phase II clinical trial design to evaluate the feasibility, safety and preliminary efficacy of combining fecal Fecal Microbiota Transplantation （FMT） Combined With SHR-1701plus Nab-paclitaxel and Gemcitabine as first-line treatment in patients for locally advanced or metastatic pancreatic ductal adenocarcinoma （PDAC）.

Participants needed: 60
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Tianjin Medical University Cancer Institute and HospitalUpdated: Oct 1, 2026Locations: 1
Eligibility criteria

18-75 years [+6]

Patients with metastatic disease, peritoneal metastasis, malignant ascites, or u... [+5]

Read more
Status: Recruiting

The KN510713 Study in Combination With mFOLFIRINOX

This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).

Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 19-75Biological sex: AllType: InterventionalSponsor: New Cancer Cure-Bio Co.,Ltd.Updated: Apr 13, 2026Locations: 1
Eligibility criteria

Adult male and female subjects aged 19 to 75 years at the time of providing writ... [+7]

History of any malignancy other than pancreatic cancer within 5 years prior to s... [+16]

Read more